No Data
No Data
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Bernstein Maintains Outperform on Natera, Raises Price Target to $135
Natera Shares Are Trading Higher After Canaccord Genuity Maintained a Buy Rating on the Stock and Raised Its Price Target From $145 to $150.
Looking Into Intellia Therapeutics's Recent Short Interest
7 Analysts Have This To Say About Intellia Therapeutics
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
103721817 : stock exchange
Boganji4 : hello
103698043 : Bought some TMF last month, started to gain